$MRNA
Added 2024-09-13 08:57:58 +0000 UTC$MRNA has lowered their FY25 Forecast and the share price took a hit and dropped -12%
They then followed it up with some cost cutting measures, including a $1 Billion reduction in R&D spending
Not really what shareholders want to hear when this is primarily a company that creates new pharmaceutical products.
Price is down to its October 2023 low, after losing all Fib supports, so if $62 is lost, there is a lot of downside here to ATL's at $11.
There is no guarantee that $MRNA will find support on $62.
